Revakinagene taroretcel
Medication
From Wikipedia, the free encyclopedia
Revakinagene taroretcel, sold under the brand name Encelto, is an allogeneic encapsulated cell-based gene therapy used for the treatment of macular telangiectasia type 2.[1][3] Revakinagene taroretcel is administered into the recipient's eye during a single surgical procedure.[4]
| Clinical data | |
|---|---|
| Trade names | Encelto |
| Other names | NTC-201-6A, revakinagene taroretcel-lwey |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625063 |
| License data | |
| Routes of administration | Intravitreal implantation |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| UNII | |
| KEGG | |
Revakinagene taroretcel works by expressing recombinant human ciliary neurotrophic factor, which is a factor that may promote the survival and maintenance of the macular photoreceptors.[4]
Revakinagene taroretcel was approved for medical use in the United States in March 2025.[4][2]
Medical uses
Revakinagene taroretcel is indicated for the treatment of adults with idiopathic macular telangiectasia type 2.[1][2]
Macular telangiectasia type 2 is a rare progressive disease of the macula (portion of the eye that process sharp central vision), leading to degeneration of the photoreceptors which are specialized light-detecting cells in the back of the eye.[4]
Society and culture
Legal status
Revakinagene taroretcel was approved for medical use in the United States in March 2025.[2][5]
Names
Revakinagene taroretcel is the international nonproprietary name[6] and the United States Adopted Name.[7]
